Top Nanotechnology Stocks To Watch Now – October 4th

Onto Innovation, Nano Dimension, and Clene are the three Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks are publicly traded companies engaged in researching, developing and commercializing technologies that manipulate matter at the nanoscale (roughly 1–100 nanometers). These firms target applications in sectors such as electronics, healthcare and advanced materials, aiming to exploit unique physical and chemical properties that emerge at extremely small dimensions. Investors in nanotechnology stocks seek high-growth potential from breakthrough innovations but should be prepared for greater volatility and long development timelines. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.